Dr. Alex Barkas
Dr. Barkas, who joined our board of directors in 2007, is a managing director and co-founder of Prospect
Venture Partners, a venture capital firm. He is chairman of the board for Geron Corp. and Tercica, Inc.
and serves on the board of directors for Amicus Therapeutics, Inc. and several private life
sciences companies.
From 1991 to 1997, he was a partner at Kleiner Perkins Caufield & Byers, where he focused on biotechnology
and medical device company investments. Prior to Kleiner Perkins, Alex was co-founder of BioBridge Associates,
a health care industry consulting firm.
Alex received a Ph.D. in biology from New York University and a B.A. in biology from Brandeis University,
where he is currently chairman of the University Science Advisory Council and serves on
the board of trustees.
Dr. C. Thomas Caskey
Dr. Caskey is an adjunct partner at Essex Woodland Health Ventures. He is Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, and holds The George and Cynthia Mitchell Distinguished Chair in Neurosciences at the University of Texas Health Science Center-Houston. Dr. Caskey has served as past president of the American Society of Human Genetics, the Human Genome Organization and Texas Academy of Medicine, Engineering and Science. Among other noteworthy roles in academia and private industry, he was senior vice president, human genetics and vaccines discovery at Merck Research Laboratories, West Point and was president of the Merck Genome Research Institute. Dr. Caskey received his M.D. from Duke University and is board certified in Internal Medicine and Medical Genetics.
Dr. Carl L. Gordon
Dr. Gordon is Co-Head of Private Equity and founding General Partner of OrbiMed Advisors, where he is active in both private equity and small-capitalization public equity investments. Before OrbiMed, Dr. Gordon was senior biotechnology analyst at Mehta and Isaly, and is a Certified Financial Analyst. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology with his dissertation focusing on protein folding and assembly. He completed a fellowship at The Rockefeller University, earned a Bachelor’s degree from Harvard College.
Dr. Clifford Reid
Dr. Clifford Reid, chairman, president and chief executive officer of Complete Genomics, has 25 years of
experience in startup and growth companies managing the commercialization of innovative unstructured data
management technologies. In 1995, he was the founding chairman and chief executive officer of Eloquent,
Inc., a digital video communications company that he took public in 2000 (NASDAQ: ELOQ) and sold it in
2003. In 1988, he was the founding vice president of product development at Verity (NASDAQ: VRTY), an
enterprise text search engine company that was recently sold to Autonomy for $500M. Cliff earned a B.S.
in physics from the Massachusetts Institute of Technology (MIT), an M.B.A. from the Harvard Business
School and a Ph.D. in management science and engineering (MSE) from Stanford University.
Dr. Drew Senyei
Dr. Senyei, managing director of Enterprise Partners since 1988, has more than 20 years of experience in
building emerging life science and healthcare companies.
Drew has served on the boards of more than 25 private and public companies. In addition, he serves on the
board of trustees of Northwestern University and on the Advisory Council at University of California, San
Diego’s Jacobs School of Engineering. He is past president of the San Diego Opera and
serves as a board member.
Drew is credited with 30 patents and more than 45 publications in peer-reviewed journals including the
New England Journal of Medicine and Proceedings of the National Academy of Science. He is the inventor
of the first FDA-approved diagnostic test to predict premature birth (through detection of fetal fibronectin),which has
been used worldwide by more than one million women at risk for preterm birth. He is the recipient of the
1998 Jonas Salk Mentor in Medicine Award from the March of Dimes and of the University of California at
Irvine Distinguished Alumni Award. Drew was named one of the Top 100 VCs in the U.S. in Forbes magazine’s
2006 Midas Touch List. He is the recipient of the 2007 Ernst & Young San Diego Master Entrepreneur Award
and received a Tony award as one of the producers of the hit Broadway musical “The Jersey Boys.”
Drew received his M.D. from Northwestern University and completed his residency training in obstetrics and
gynecology at the University of California, Irvine, where he served on the faculty prior to focusing full
time on venture capital funding for early-stage medical companies.
Charles P. Waite, Jr.
Mr. Waite is a managing director at OVP Venture Partners with more than 25 years of experience in both the
management and investment sides of emerging growth companies. He focuses on investments in the digital
biology and network security sectors.
His venture investments include Accelerator, Airgo Networks, Altus, Cardima, CellPro, CODA Genomics,
Complete Genomics, Filenet, GenoLogics, Loudeye Technologies, NanoString, Plectix BioSystems, Quantum
Medical, Raytel Medical, Returns Online, Rosetta Inpharmatics, SafeHarbor, Seattle Genetics, Serengeti,
Verity and WatchGuard. He currently serves on the board of directors of Accelerator, Altus, CODA Genomics,
Complete Genomics, GenoLogics, NanoString, Plectix BioSystems, and SafeHarbor.
Prior to joining OVP in 1987, Chad was a general partner at Hambrecht & Quist Venture Partners. Prior to that,
he worked in marketing and sales management at Cobe Laboratories, Inc.’s Cardiovascular
Medical Products Division.
Chad received his B.A. in history from Kenyon College and his M.B.A. from Harvard Business School. He is a
board member of the NVCA and the Washington Technology Alliance. He is also a trustee at Kenyon College, a
member of the Oregon Health Sciences University BSIF Advisory Board and a member of the University of
Washington’s Technology Transfer Advisory Board.
Top of page